GO
Loading...

Biogen Idec Inc

More

  • Get risk-on into year end: Mainstay advisor Friday, 7 Nov 2014 | 2:30 PM ET
    David Kudla, Mainstay Capital Management CEO & Chief Investment Strategist

    Stocks are set to roar higher through the end of the year."The value is in growth right now," says David Kudla of Mainstay Capital Management says.

  • Oct 24- Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder. Other approved hemophilia B treatments include Baxter's Rixubis, Pfizer Inc's Benefix and CSL Behring Ltd's Mononine. Baxter's shares were up about 1 percent at $69.66 in early...

  • Oct 24- Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder. Obizur will compete with Biogen Idec Inc's Eloctate, which was approved in June. Other approved hemophilia B treatments include Baxter's Rixubis, Pfizer Inc's Benefix and CSL...

  • Japan's Nikkei share average fell 0.5 percent while MSCI's broadest index of Asia-Pacific shares outside Japan dropped 0.2 percent. The flash HSBC/ Markit manufacturing purchasing managers' index edged up to a three-month high of 50.4 from a final reading of 50.2 in September, and just a hair's breadth from the 50.3 reading forecast by analysts.

  • TOKYO, Oct 23- Asian shares sagged on Thursday after a retreat on Wall Street and falling crude oil prices revived investor concerns over slowing global growth, as markets nervously waited for Chinese and European manufacturing reports later in the day. Japan's Nikkei share average fell 0.8 percent while MSCI's broadest index of Asia-Pacific shares outside...

  • Wall Street fell as Boeing Co and Biogen Idec tumbled after their results disappointed investors, the two biggest drags on the S&P 500.. The retreat on Wall Street pulled MSCI's gauge of global equity performance lower, but European stocks closed higher, largely driven by earnings. GlaxoSmithKline rose 2.6 percent in London after saying it expects an Ebola...

  • NEW YORK, Oct 22- U.S. stocks turned lower in afternoon trading on Wednesday, with major indexes erasing earlier gains as a shooting at the Canadian parliament unnerved investors and Boeing and Biogen sold off following results. Market benchmarks began drifting lower in late morning after a gunman fatally wounded a soldier in Ottawa, the Canadian capital, and...

  • Oct 22- Biogen Idec Inc said on Wednesday sales of its big-selling new multiple sclerosis drug Tecfidera fell short of Wall Street's lofty expectations, and the company confirmed a serious brain infection in a patient who took the oral medication, sending its shares 7 percent lower. The drug, which has far exceeded expectations since its March 2013 U.S. approval,...

  • Biogen profit surges; Tecfidera sales disappoint Wednesday, 22 Oct 2014 | 1:50 PM ET
    A multiple sclerosis drug is manufactured at the Biogen Idec plant in Cambridge, Mass.

    Sales of Biogen Idec's new multiple sclerosis drug Tecfidera fell short of Wall Street estimates for the first time. Its shares fell nearly 3 percent.

  • US STOCKS-Wall St turns lower as Boeing, Biogen weigh Wednesday, 22 Oct 2014 | 1:06 PM ET

    *Broadcom and Yahoo rally after results. NEW YORK, Oct 22- U.S. stocks turned lower in afternoon trading on Wednesday, with major indexes erasing earlier gains as both Boeing and Biogen sold off following their results. Biogen Idec was the biggest drag on the S&P 500, falling 7 percent to $303.88 after the company reported sales of its big-selling new multiple...

  • Biogen shares fall after Tecfidera patient dies Wednesday, 22 Oct 2014 | 11:48 AM ET

    The patient, who was taking Tecfidera, died earlier this month.

  • Oct 22- Biogen Idec Inc on Wednesday reported sales of its big-selling new multiple sclerosis drug, Tecfidera, that fell short of Wall Street's lofty expectations, and the company confirmed a serious brain infection in a patient who took the oral medication, sending its shares about 8 percent lower. Shares of the U.S. biotechnology firm fell $24.29 to $302.48 on...

  • Late Tuesday, both Yahoo Inc and Broadcom beat on revenue. Dow component Boeing edged 0.3 percent higher to $127.50 after its results, while Dow advanced 4 percent to $50.13. Yahoo climbed 5.4 percent to $42.34 while Broadcom added 6.3 percent to $39.70.

  • Oct 22- Sales of Biogen Idec Inc's big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time and its shares fell nearly 3 percent, even as the company reported higher-than-expected third-quarter profit and raised its full-year earnings forecast. Biogen raised its full-year adjusted earnings...

  • Early movers: BA, DOW, SWK, TSLA, YHOO Wednesday, 22 Oct 2014 | 8:41 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • NEW YORK, Oct 22- Boeing Co and Dow Chemical were among the biggest movers of Wednesday's premarket session, with both stocks higher in the wake of strong results. Dow Chemical rose 2.7 percent to $49.50 before the bell after the company also reported better-than-expected earnings, helped by higher sales in its plastics and performance materials business...

  • Oct 22- Biogen Idec Inc on Wednesday reported much higher-than-expected third-quarter profit and the company raised its full-year earnings forecast, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time. Citing updated business development expectations, Biogen raised its...

  • Oct 22- Biogen Idec Inc on Wednesday reported much higher third-quarter profit and revenue, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time. The U.S. biotechnology company's net profit jumped to $856.1 million, or $3.62 per share, from $487.6 million, or $2.05 per share, a year ago.

  • Earnings set to drive markets again Wednesday, 22 Oct 2014 | 5:55 AM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.

  • Earnings set to take markets' center stage Tuesday, 21 Oct 2014 | 7:29 PM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.